Despite the traditionally assumed and well-validated antitumor capacity of IFNγ, there is also growing evidence for a more ambiguous role of this cytokine in the fine-tuning of CD8+ T cell-driven CRC defense. The gene discussed is CD8A; the disease is colorectal carcinoma.